Trying to condense three, incredibly personal RPGs into a streamlined narrative would only disappoint. The Mass Effect show ...

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE ... Results from two Phase 3 trials evaluating the effect on patient-reported outcomes in patients with chronic refractory gout treated with SEL-212.

Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural's IL-18 variants, reinforcing ...

Upcoming topline results from the ongoing TX45 clinical program includes Phase 1b hemodynamic, proof-of-concept trial data expected in late 1Q or early 2Q’2025, and APEX Phase 2 clinical trial data ...

The company expects to submit an Investigational New Drug (IND) Application for its IL-18 program ... Meeting of the Society ...

A meme purports to outline what it calls "The Trump-Vance Project 2025 Plan," although both U.S. President-elect Trump and ...

“It selectively reduces fat while increasing muscle, establishing a new ... mass, marking it as a potential game-changer in obesity management. HM17321 addresses a key limitation in current ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

Ford lost 80 pounds in over a year and a half, and running—something she’d avoided since childhood—took on a new appeal.

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.